Acute and late toxicities of radiotherapy for patients with discoid lupus erythematosus: a retrospective case-control study by Patel, Ajaykumar B et al.
RESEARCH Open Access
Acute and late toxicities of radiotherapy for
patients with discoid lupus erythematosus:
a retrospective case-control study
Ajaykumar B Patel
1, Christopher L Hallemeier
1, Ivy A Petersen
1, Ashley W Jensen
1, Thomas G Osborn
2 and
Robert C Miller
1*
Abstract
Background: The purpose of this study was to evaluate acute and late toxicities of radiotherapy for patients with
discoid lupus erythematosus (DLE).
Methods: A retrospective review was performed of patients with DLE who received radiotherapy at our institution
between 1980 and 2005. Patients with other connective tissue disorders were excluded. Control patients were
matched 2:1 with the DLE treatment courses based on age, cancer diagnosis, year of treatment, radiotherapy dose,
and sex. Acute (within 30 days from the completion of radiotherapy) and late toxicities were evaluated for each
treatment course using the Common Terminology Criteria for Adverse Events Version 3.0.
Results: Twelve patients with DLE received a total of 15 radiotherapy courses. The median follow-up time was 2.6
years (range, 0.0-15.2 years). Acute toxicity of any organ was observed in 10 (67%) treatment courses, of which 2
(13%) were Grade 3 or higher. Acute Grade 1 or 2 dermatologic toxicity was observed in 8 courses (53%). Late
toxicity of any organ was observed in 7 of 12 (58%) evaluable treatment courses, of which 3 (23%) were grade 3 or
higher. Late grade 1 or 2 dermatologic toxicity was observed in 5 (42%) courses. No patient experienced acute or
late Grade 3 or higher dermatologic toxicity. The rates of any organ or dermatologic acute and late toxicity were
not significantly different between DLE and control treatment courses.
Conclusions: Our findings do not suggest an increased risk of toxicity to the skin or other organs in patients with
DLE receiving radiotherapy.
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Background
Discoid lupus erythematosus (DLE) is a subtype of cuta-
neous lupus erythematosus that is characterized by circu-
lar, red, patchy skin plaques (termed “discoid lesions”).
These lesions usually appear on the scalp, cheeks, and
nose but can also affect the neck, chest, back, and other
areas of the head and body. Fifty percent of discoid
lesions are found on hair-bearing scalp regions [1]. Diag-
nosis is differentiated from subacute cutaneous lupus
because DLE can result in chronic scarring. Discoid
lupus also is associated with increased photosensitivity,
increased risk of sunburn, and discoid lesions exacer-
bated by sunlight. DLE is differentiated from systemic
lupus erythematosus (SLE) in that patients with DLE
have skin lesions only; whereas, patients with SLE have
systemic features meeting the American College of Rheu-
matology SLE criteria. However, approximately 5-10% of
patients diagnosed with DLE eventually develop SLE.
The cause of DLE is unknown but may be due to an
autoimmune disorder. It is a relatively rare disorder com-
pared with SLE and generally affects more women than
men. Diagnosis of DLE is confirmed with a skin biopsy.
Total clearance of skin lesions can be achieved with early
treatment consisting of potent topical corticosteroids and
antimalarial agents; failure of treatment can lead to per-
manent scarring [1]. Newer therapies for DLE include
* Correspondence: miller.robert@mayo.edu
1Department of Radiation Oncology, Mayo Clinic, 200 First St SW, Rochester,
MN 55905, USA
Full list of author information is available at the end of the article
Patel et al. Radiation Oncology 2012, 7:22
http://www.ro-journal.com/content/7/1/22
© 2012 Patel et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.pulsed dye laser treatment, phototherapy, and efalizumab
(an anti-CD11a antibody) [2-4].
Many case reports in the literature have detailed unusual
toxicity after radiotherapy in select patients with connec-
tive tissue disorders (CTD) such as rheumatoid arthritis,
DLE, SLE, polymyositis, dermatomyositis, and sclero-
derma, but retrospective studies have reported more mod-
est toxicity data in small groups of patients [5-7]. To our
knowledge, no study has exclusively examined adverse
effects of radiotherapy for patients with DLE. Because
DLE is a disorder characterized by inflammatory attacks
on the skin and by photosensitivity, it raises concerns
about increased toxicity from radiotherapy.
This article is the third in a series of studies conducted
at Mayo Clinic that assessed radiotherapy outcomes of
cancer patients with CTD. The first and second analyses
focused on systemic scleroderma and SLE, respectively
[8,9]. The current study aimed to evaluate our institution’s
experience with late and acute toxicities of radiotherapy
for patients with DLE.
Methods
We queried the institutional master diagnosis database to
identify patients with DLE treated at Mayo Clinic (Roche-
ster, Minnesota) from January 1, 1980, through Decem-
ber 31, 2005. Records were cross-referenced against
patient treatment records from the Department of Radia-
tion Oncology to create the initial list of subjects with
DLE who received radiotherapy. The diagnosis of DLE
was confirmed by manually searching records for evi-
dence of discoid rash. Patients with a confirmed diagno-
sis of SLE or with more than 4 American College of
Rheumatology SLE criteria were included in a previous
report on SLE [9] and excluded from the current investi-
gation. Patients with other CTDs, including scleroderma
and rheumatoid arthritis, also were excluded. Case con-
t r o l sw e r ei d e n t i f i e db ys e a r c h i n gt h eD e p a r t m e n to f
Radiation Oncology database. Controls were matched 2:1
with the DLE treatment courses based on age, cancer
diagnosis, year-of-treatment, dose, and sex.
Toxicities were evaluated using the Common Terminol-
ogy Criteria for Adverse Events version 3.0 [10]. Toxic
events were considered acute if they occurred during
treatment or within 30 days after treatment completion.
Events after 30 days were considered late toxicities. Each
treatment course was evaluated for toxicities (some
patients had more than 1 treatment). Survival rate and fol-
low-up time were calculated from the radiotherapy com-
pletion date.
Patient characteristics and treatment characteristics
were compared between the DLE patients and the controls
using the 2-tail Fisher’s exact test or one way analysis of
variation (ANOVA), where appropriate. In the DLE
patients, several patient and treatment characteristics were
examined for an association with acute toxicity using the
2-tail Fisher’s exact test or late toxicity using the log-rank
test. Variables examined included age at radiotherapy (>
64 vs. ≤ 64), age at DLE diagnosis (> 59 vs. ≤ 59), surgical
treatment (yes vs. no), chemotherapy administration (yes
vs. no), patient sex (male vs. female), photosensitivity (pre-
sence vs. absence), timing of DLE diagnosis relative to
initiation of radiotherapy (before vs. after), total radiother-
apy dose (> 52.8 Gy vs. ≤ 52.8 Gy), dose per fraction (> 2
Gy vs. ≤ 2 Gy), treatment intent (curative vs. palliative),
treatment site (breast, head and neck, pelvis, or thorax vs.
other). Kaplan-Meier statistics were used to calculate late
toxicity rates [11]. Acute and late toxicities rates were
compared between the DLE treatment courses and the
control treatment courses using the 2 tail Fisher’se x a c t
test and the log-rank test, respectively. A p-value of < 0.05
was considered significant. The statistical software used
for analysis was JMP (SAS Institute Inc, Cary, North
Carolina).
Results
We identified 12 patients with a diagnosis of DLE who
received a total of 15 courses of radiotherapy (1 patient
received 2 courses and 1 patient received 3 courses). We
identified 30 unique controls receiving 30 courses of
radiotherapy. Patient and treatment characteristics for
DLE patients and controls are detailed in Tables 1 and 2;
there were no statistically significant differences between
the two groups. For the DLE patients, 2 (17%) were alive
and 10 (83%) had died (3 died of cancer) with a median
follow-up time of 2.6 years (range, 0.0-15.2 years). For
the control patients, 8 (27%) were alive and 28 (73%) had
died (6 from cancer) with a median follow-up of 3.3 years
(range 0.0-19.1 years).
Acute toxicities
In the DLE patients, 10 of the 15 treatment courses
(66%) were associated with any-grade acute toxicities.
Two courses (13%) were associated with grade 3 or
higher acute toxicities (grade 4 mucositis during tonsil-
lar radiotherapy and grade 3 neck and back pain shortly
after spine radiation). Eight courses (53%) were asso-
ciated with grade 1 or 2 acute dermatologic toxicities
(erythema in 6 courses, infection in 1 course, and pruri-
tus in 1 course). No acute dermatologic toxicities higher
than grade 2 were observed. All acute dermatologic toxi-
cities subsided within 30 days. No treatment courses
were interrupted because of acute toxicities. Univariate
analysis did not show any statistically significant correla-
tion between patient or treatment characteristics and
any-grade, grade 3 or higher, or dermatologic acute
toxicity.
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(90%) were associated with any-grade acute toxicities.
One course (3%) was associated with grade 3 or higher
acute toxicity (grade 4 pulmonary embolus). Eight
courses (27%) were associated with grade 1 or 2 acute
dermatologic toxicities. No acute dermatologic toxicities
higher than grade 2 were observed.
Univariate analysis did not show a statistically signifi-
cant difference in acute toxicity rates (any grade, grade
3 or higher, or dermatologic) between the DLE courses
and the control courses.
Late toxicities
In the DLE patients, only 13 of the 15 courses were
assessed for late toxicities (for 2 courses, no followup was
available beyond 30 days). Seven of the 13 courses (54%)
were associated with evidence of late toxicity. Three
courses (23%) were associated with grade 3 late toxicity
(low back pain and nocturia with 1 course, neck pain
with 1 course, and conductive hearing loss with 1
course.) No grade 4 or 5 late toxicity was observed. Five
courses (38%) were associated with late grade 1 or 2 late
dermatologic toxicities (telangiectasia with 2 courses, alo-
pecia with 1 course, actinic keratosis with 1 course, and
unspecified perioral rash with 1 course). No late derma-
tologic toxicities higher than grade 2 were observed. The
median time to any grade of late toxicity was 1.4 years
(range, 0.3-12.5 years). The Kaplan-Meier estimates of all
grades late toxicities at 2 years and 5 years were 72% for
both (Figure 1A). The Kaplan-Meier estimates of grade 3
or higher late toxicities at 2 years and 5 years were 15%
and 27%, respectively (Figure 1B). Univariate analysis did
not show any statistically significant correlation between
patient or treatment characteristics and any-grade, grade
3 or higher, or dermatologic late toxicity.
In the controls, only 26 of the 30 treatment courses were
evaluated for late toxicities (for 4 courses, no followup was
available beyond 30 days). Eight out of 26 courses (31%)
were associated with late toxicity of any grade. One course
(4%) was associated with grade 3 late toxicity. No grade 4
or 5 late toxicities were observed. Seven courses (27%)
were associated with grade 1 or 2 late dermatologic toxi-
city. No late dermatologic toxicities higher than grade 2
were observed.
Univariate analysis did not show a statistically signifi-
cant difference in late toxicity rates (any grade, grade 3
or higher, or dermatologic) between the DLE courses
and the control courses.
Table 1 Patient Characteristics
Characteristic DLE (n = 12)* Controls (n = 30)
Female sex, No. of patients (%) 6 (50) 10 (33)
Race, white, No. of patients (%) 12 (100) 30 (100)
Age, median (range), y
At radiotherapy 69 (55-82) 65 (51-86)
At initial DLE symptoms 47 (9-79) -
At DLE diagnosis 45 (11-79) -
DLE diagnosis
Established before radiotherapy, No. of patients (%) 9 (75) -
Established after radiotherapy, No. of patients (%) 3 (25) –
Time between DLE diagnosis and radiotherapy, median (range), y –
Diagnosis first 9.0 (2.2-27.0) -
Radiotherapy first 3.1 (1.7-6.3) -
American College of Rheumatology systemic lupus erythematosus characteristic, No. of patients (%)
Discoid rash 12 (100) -
Photosensitivity 9 (75) -
Primary tumor location, No. of patients (%)
Prostate 4 (33) 8 (26)
Breast 2 (17) 4 (13)
Lung 2 (17) 8 (26)
Oral 2 (16) 6 (20)
Anus 1 (8) 2 (6)
Bladder 1 (8) 2 (6)
Abbreviation: DLE, discoid lupus erythematosus
* 1 patient received 2 treatment courses and 1 patient received 3 treatment courses
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Characteristic DLE (n = 15) Controls (n = 30)
Intent of treatment, No. of treatments (%)
Curative 12 (80) 24 (80)
Palliative 3 (20) 6 (20)
Anatomic target of radiotherapy, No. of treatments (%)
Head and neck 3 (20) 6 (20)
Prostate 3 (20) 6 (20)
Breast 2 (13) 4 (13)
Thorax 2 (13) 4 (13)
Spine 2 (13) 4 (13)
Bladder 1 (7) 2 (7)
Brain 1 (7) 2 (7)
Pelvis 1 (7) 2 (7)
Radiotherapy technique, No. of treatments (%)
External beam radiotherapy, 2-dimensional 13 (87) 28 (93)
External beam radiotherapy, 3-dimensional 1 (7) 0 (0)
Iodine brachytherapy 1 (7) 2 (7)
Radiotherapy dose, median (range)
Dose per fraction, Gy 2.0 (1.2-8.0) 2.0 (1.6-4.0)
No. of fractions 28 (1-50) 30 (2-42))
Total dose, Gy 52.8 (8.0-66.0) 58.8 (8.0-66.6)
Biologically equivalent dose, Gy, median (range)
Gy3 31.8 (18.2-45.5) 39.5 (24.3-45.5)
Gy10 19 (5.6-13.9) 12.3 (3.3-16.7)
Chemotherapy before or after 60 d of radiotherapy
No 12 (80) 23 (76)
Yes 3 (20) 7 (24)
Surgery before or after 60 d of radiotherapy
No 12 (80) 23 (76)
Yes 3 (20) 7 (24)
Abbreviation: DLE, discoid lupus erythematosus
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Figure 1 Kaplan-Meier estimates of any grade (A) and grade 3-5 (B) late toxicity with DLE patient treatment courses (n = 13) and
control patient treatment courses (n = 26). Log-Rank p-values were > 0.05 for both comparisons.
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In this retrospective study of patients with DLE who
received radiotherapy at our institution, severe (grade 3
+) acute or late toxicity was infrequent. No acute or late
dermatologic toxicity greater than grade 2 was observed.
The incidence of acute and late toxicity in DLE patients
was similar to that of matched controls. Thus, our data
suggest that radiotherapy can be administered safely in
patients with DLE.
CTDs such as DLE and SLE have long been thought
to increase the risk of radiotherapy-related toxicities
[12]. Concerns stem from the possibility of pathologic
damage to microvasculature, which could lead to fibro-
sis, and other effects. The hypothesis that patients with
CTDs potentially have increased radiosensitivity is sup-
ported by numerous case reports that have described
exaggerated complications after radiotherapy in patients
with collagen vascular diseases [13-15]. Nevertheless,
larger, retrospective studies [8,9,12,16-18] and a pooled
data analysis from Holscher et al. [6] have suggested an
increased, but less dramatic, risk of higher toxicity in
patients with CTD who receive radiotherapy. The largest
study to date of patients with CTD was conducted by
Morris and Powell [16]; they included 209 patients with
various collagen vascular diseases who received radio-
therapy. The authors concluded that patients with non-
rheumatoid arthritis CTDs had an increased risk of late
toxicities with radiotherapy and that treatment decisions
should be made on a case-by-case basis for radiosensi-
tive patients. Research at Mayo Clinic has suggested
that risk of late complications after radiotherapy
increases with the increasing severity of the underlying
CTD [19].
Concerns about toxicity have led to a marked reduc-
tion in radiotherapy for patients with CTDs. A study by
Benk et al. [20] showed that only 10% of patients with
SLE referred for radiotherapy received treatment,
although 65% of patients without CTDs typically are
treated. They also showed that the patients receiving
treatment did not have any unusual toxicity. The
authors concluded that radiotherapy may be inappropri-
ately withheld from patients with SLE and cancer.
Several case reports have noted an increased risk of
toxicity in patients with DLE [5,21,22]. De Naeyer et al.
[5] reviewed the literature on patients with CTD receiv-
ing radiotherapy and described a single patient who had
2 courses of radiotherapy, one before the onset of DLE
and another 3 years later. The patient experienced
severe acute and late toxicity only after the second treat-
ment course. Eedy and Corbett [21] described a patient
who received radiotherapy to the chest 10 months after
a diagnosis of DLE. Within 10 days of treatment, char-
acteristic discoid lesions developed in the precise region
of the radiation field. Treatment with topical corticoster-
oids and chloroquine resolved the lesions. His original
erythematous regions on the cheeks and nose remained,
and no other toxicities were noted. Ishida-Yamamoto et
al. [22] detailed a patient with a discoid lesion exacer-
bated by radiotherapy for lymphoma. A biopsy diagnosis
of DLE was made when the nodule grew larger. Treat-
ment with a topical corticosteroid resulted in dramatic
improvement and left only a scar. The patient had no
episodes of DLE recurrence in 4 years of follow-up.
In contrast to these case reports, no patient in our
study had acute or late dermatologic toxicities higher
than grade 2. None of the patients in our study had
clinically significant exacerbation or development of dis-
coid lesions with radiotherapy. Importantly, we note
that none of the patients had clear evidence of discoid
lesions in the radiation field before therapy. We did
note that the risk of grade 3 or higher late toxicity was
numerically higher in the DLE group compared to the
control group, although this difference was not statisti-
cally significant. The small sample size in the present
study limits the ability to exclude a small but statistically
significant difference in late toxicity. However, the
observed late grade 3 toxicities were interpreted as
expected toxicities of radiation unrelated to DLE. Addi-
tionally, it is reassuring that there were no late grade
4-5 toxicities observed.
There are limitations to the conclusions that can be
drawn from our current investigation. This was a retro-
spective chart review, thus unappreciated biases may
have been present. The sample size was small, thus lim-
iting the ability to identify potential patient and/or treat-
ment factors associated with increased toxicity. The
patient population and radiotherapy treatments adminis-
tered were heterogeneous. No patient in our series had
documented discoid lesions in the radiotherapy treat-
ment field, thus the safety of administering radiotherapy
in this setting remains undefined. In spite of these lim-
itations, this is to our knowledge the largest series of
patients with DLE and radiotherapy reported to date in
the medical literature. Further studies are needed to
confirm or refute the safety of radiotherapy in patients
with DLE and to identify potential prognostic factors
that may predict for increased toxicity.
Conclusions
In our cohort of patients with DLE, severe dermatologic
toxicity from radiotherapy was not observed. DLE
should not be considered an absolute contraindication
to radiotherapy. However, previous case reports suggest
that precautions should be taken if discoid lesions are
present in the radiation field. Although previous studies
suggest a modest increase in the risk of late toxicity
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Page 5 of 6with radiotherapy in the setting of CTDs, the current
study found no evidence supporting a prohibitive
increase in the incidence of grade 3 or higher late toxici-
ties after radiotherapy in patients with DLE. Decisions
on radiotherapy in patients with CTD should be made
on an individual basis and consider the risks posed by
the malignant disease.
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